In angiotensin-converting enzyme inhibitor-intolerant individuals, the angiotensin receptor blocker telmisartan does not reduce the incidence of major cardiovascular events in high-risk patients: lessons learned from the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects Wtih Cardiovascular Disease (TRANSCEND).
Bloch
Michael J
MJ
Division of General Internal Medicine, University of Nevada School of Medicine, Reno, NV, USA. mbloch@aol.com
Basile
Jan N
JN